Breast Neoplasm Clinical Trial
Official title:
Feasibility of Preoperative Tattooing of Percutaneously Biopsied Axillary Lymph Node: A Quasi Experimental Pilot Study
This study evaluates utility of a novel technique using India Ink to aid in the
identification and retrieval of axillary lymph nodes during surgery, in breast cancer
patients with suspicious lymph nodes.
The first part of the study will evaluate the feasibility of the technique in patients who
commence their treatment with surgery. Provided its success, the second part of the study
will evaluate the applicability of this same technique in patients who receive chemotherapy
before having surgery.
Breast cancer is the leading cause of cancer mortality among females. Sentinel lymph node
biopsy helps avoid axillary lymph node dissection and the associated morbidity. However, its
utility is unclear in patients with biopsy proven axillary disease that has been treated with
neoadjuvant chemotherapy. The objective of our study is to evaluate a) the feasibility of a
novel technique of preoperatively tattooing suspicious lymph nodes with India ink, their
intraoperative identification and retrieval in patients undergoing upfront breast and
axillary surgery(Phase I); and b) the application of this technique in patients who undergo
surgery after receiving neo-adjuvant chemotherapy i.e. lag time between tattooing and lymph
node retrieval (Phase II) with the ultimate objective to see if the status of the excised
sentinel and tattooed lymph node will be predictive of the status of the axilla.
A quasi-experimental pilot study will be conducted to evaluate the feasibility of tattooing
suspicious lymph nodes with sterile black India ink. The study will be conducted in two
phases, with the second phase conditional upon the successful results of the first. In Phase
I, only 10 patients who are committed to undergo upfront surgery (without neoadjuvant
chemotherapy) will be included. These patients will have the suspicious lymph node tattooed
by injecting India ink at the time of ultrasound guided core needle biopsy. Intraoperatively,
the axilla will be inspected to determine whether India ink tattooed in the lymph nodes can
be visualized by the surgeon. Microscopic inspection for the presence of the dye in nodes
retrieved by sentinel biopsy and/or axillary dissection will also be done. In Phase II, this
process will be repeated for patients who undergo surgery after neoadjuvant chemotherapy and
concordance between the sentinel, tattooed and non-sentinel nodes will be determined.
Ethical approval was obtained from the Aga Khan University Ethical Review Board (ERC#
2018-0345-1105). The process of sentinel node biopsy is a safe and routinely performed
procedure at our institution. Intradermal injection of methylene blue can lead to skin
necrosis; intra-parenchymal injection can cause induration and erythema with associated pain.
These side effects can be minimized by diluting methylene blue which will be done. The
complications that can result from all additional steps of study procedures will be discussed
with the patient and their full responsibility will be borne by the institution. Although
sterile black India Ink is safe to administer but possible side effects can include mucosal
inflammation due to spillage of the ink, abscess formation and others such as an allergic
reaction. If any of these situations are encountered full responsibility to treat the side
effects will be borne by the study team using departmental funds.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03273426 -
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
|
N/A | |
Recruiting |
NCT04583124 -
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02913573 -
Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction
|
Phase 2 | |
Completed |
NCT03124095 -
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer
|
N/A | |
Terminated |
NCT00251095 -
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT05576545 -
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
|
N/A | |
Active, not recruiting |
NCT03625635 -
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
|
N/A | |
Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
Withdrawn |
NCT03266562 -
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
|
N/A | |
Completed |
NCT00530868 -
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06255808 -
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
|
||
Completed |
NCT04640220 -
Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors
|
N/A | |
Completed |
NCT02970682 -
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02316561 -
Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer
|
N/A | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06056414 -
Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation
|
N/A | |
Recruiting |
NCT05427071 -
Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT03740893 -
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
|
Phase 2 |